Mean EBV load in RA patients treated with Tocilizumab.

<p>Epstein Barr virus copy number per 500ng PBMC DNA was assayed in 35 patients under tocilizumab. For every patient, EBV load, median and standard deviation are given every 6 months from the start till 36 months. Four patients accepted to be followed for one more year.</p

EBV load evolution under tocilizumab treatment.

<p>Each black circle indicates EBV load in one patient. Red dots indicate mean EBV load. Mean EBV load evolution is drawn as a blue line +/- 1 standard deviation (dark grey surface) indicating the LOESS (LOcally wEighted Scatter-plot Smoother) regression.</p

Mean EBV load in RA patients treated with Abatacept.

<p>Epstein Barr virus copy number per 500ng PBMC DNA was assayed in 55 patients under abatacept. For all patients, EBV load, median and standard deviation are given every 6 months from the beginning till 36 months. Four patients accepted to be followed for one more year.</p

EBV load evolution under abatacept treatment.

<p>Each black circle represents a patient’s EBV load. Red dots indicate mean EBV load every 6 months. Mean EBV load evolution is drawn as a blue line +/- 1 standard deviation (dark grey surface) displaying the LOESS (LOcally wEighted Scatter-plot Smoother) regression.</p

Patients characteristics.

<p>Patients characteristics.</p

Example of X chromosome inactivation status in 5 samples.

<p>Polymerase chain reaction products from the androgen receptor (<i>AR</i>) methylation assay shows random X chromosome inactivation (50–79%) in samples A and C, and skewed X chromosome inactivation (80–89%) in sample E. Samples B and D have a non-informative status. For each sample, DNA was either undigested (−) or digested (+) with the methylation-sensitive restriction enzyme <i>HpaII</i>. Marker (331-bp and 242-bp) fragments are visible.</p

Degrees of X chromosome inactivation (XCI) in healthy women (HW), women with rheumatoid arthritis (RA), and women with systemic sclerosis (SSc) in the French cohort (Fr).

<p>Upper part: Proportional analysis with respect to the three categories of XCI: Extreme skewing (90:10 → 100:0), Medium skewing (80:20 → 89:11), and Random (50:50 → 79:21). <i>P</i> values were from <i>Χ</i>² with Yates’ correction. Lower part: Scatter plots showing a difference of the distribution of XCI patterns in women with RA and SSc compared to HW (<i>P</i> = 0.013 and 0.009 respectively, Kolmogorov–Smirnov).</p

Comparison of X chromosome inactivation patterns and the presence of HLA-susceptibility alleles.

<p>Comparison of X chromosome inactivation patterns and the presence of HLA-susceptibility alleles.</p

Contingency analyses of X chromosome inactivation patterns in regard to various subjects’ characteristics.

<p>Contingency analyses of X chromosome inactivation patterns in regard to various subjects’ characteristics.</p

Autoantibodies against A) EphB2 and B) THEX1 analyzed in patients with scleroderma.

<p>Sera reactivity against A) EphB2 or B) THEX1 is given by Absorbance (Abs) value for patients with systemic sclerosis (SSc), patients with SSc positive for anti-topoisomerase antibody (ATA^pos), positive for anti-centromere antibody (ACA^pos) or negative for both (ACA/ATA^neg), and compared to all controls (CTLS) including healthy controls (HC) and controls with other Rheumatic diseases (RD), with a total of n = 166 with 85 HC and 81 RD for EphB2 and n = 180 with 99 HC and 81 RD for THEX1. Sera were tested at dilution 1/100 and defined as positive when Abs≥0 (on or above the dotted blue line). Red bars represent medians with interquartile ranges. Percentage of individuals positive for anti-EphB2 or THEX1 antibodies are indicated in the upper part of the graph. All P values are calculated using Mann Whitney test by comparing Abs results from patients with SSc as a whole group or in SSc subgroups to all controls (CTLS).</p